Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Modalis Therapeutics Corporation ( (JP:4883) ).
Modalis Therapeutics Corporation has completed the pay-in procedures for the issuance of 21,900 new common shares as part of a restricted-stock-based remuneration plan. This move, approved by the Board of Directors, aims to reward and incentivize directors, employees, and former employees, potentially enhancing stakeholder alignment and company performance.
More about Modalis Therapeutics Corporation
Modalis Therapeutics Corporation is a company listed on the Tokyo Stock Exchange, operating in the biotechnology industry. It focuses on developing innovative therapies, likely involving genetic or molecular approaches, to address unmet medical needs.
YTD Price Performance: -26.47%
Average Trading Volume: 2,004,315
Technical Sentiment Signal: Buy
Current Market Cap: Yen5.58B
Learn more about 4883 stock on TipRanks’ Stock Analysis page.